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Abstract
N-Glycolylneuraminic acid (Neu5Gc) is an immunogenic sugar of dietary origin that metabolically incorporates into diverse
native glycoconjugates in humans. Anti-Neu5Gc antibodies are detected in all human sera, though with variable levels and
epitope-recognition profiles. These antibodies likely play a role in several inflammation-mediated pathologies including
cardiovascular diseases and cancer. In cancer, they have dualistic and opposing roles, either stimulating or repressing
disease, as a function of their dose, and some of these antibodies serve as carcinoma biomarkers. Thus, anti-Neu5Gc
antibodies may signify risk of inflammation-mediated diseases, and changes in their levels could potentially be used to
monitor disease progression and/or response to therapy. Currently, it is difficult to determine levels of anti-Neu5Gc
antibodies in individual human samples because these antibodies recognize multiple Neu5Gc-epitopes. Here we describe a
simple and specific method for detection and overall estimation of human anti-Neu5Gc antibodies. We exploit the
difference between two mouse models that differ only by Neu5Gc-presence (wild-type) or Neu5Gc-absence (Cmah2/2
knockout). We characterize mouse serum from both strains by HPLC, lectin and mass-spectrometry analysis and show the
target Neu5Gc-epitopes. We then use Cmah2/2 knockout sera to inhibit all non-Neu5Gc-reactivity followed by binding to
wild-type sera to detect overall anti-Neu5Gc response in a single assay. We applied this methodology to characterize and
quantify anti-Neu5Gc IgG and IgA in sera of patients with Kawasaki disease (KD) at various stages compared to controls. KD
is an acute childhood febrile disease characterized by inflammation of coronary arteries that untreated may lead to coronary
artery aneurysms with risk of thrombosis and myocardial infarction. This estimated response is comparable to the average of
detailed anti-Neu5Gc IgG profile analyzed by a sialoglycan microarray. Both assays revealed an elevated response in acute
KD patients with normal coronaries compared to patients with aneurysm or dilated coronaries. Implications of these
findings are discussed.
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Introduction
Sialic acids (Sias) are 9-carbon backbone acidic sugars
terminating glycan chains of various glycoproteins and glycolipids
on vertebrate cell surfaces and secreted glycans. N-Acetylneur-
aminic acid (Neu5Ac) and its hydroxylated form, N-Glycolylneur-
aminic acid (Neu5Gc) are the two major Sia forms in mammals
[1–3]. Humans are genetically Neu5Gc-deficient due to lack of the
enzyme CMP-Neu5Ac hydroxylase (CMAH) [4,5]. Similarly, a
‘human-like’ Cmah2/2 knockout mouse model is Neu5Gc-
deficient, in contrast to wild-type mice that contain Neu5Gc in
most tissues [6–8]. Neu5Gc is rich in red meat and when
consumed by humans it metabolically incorporates into cells as
‘self’ [9,10], but at the same time becomes immunogenic [11–14].
This results in a polyclonal anti-Neu5Gc antibody response [9,15–
17], which we termed ‘xeno-autoantibodies’ [16]. It was also
suggested that bacterial infections contribute to the generation of
these anti-Neu5Gc antibodies in humans [18]. Such antibodies are
proposed to contribute to xeno-transplantation rejection, in
addition to anti alpha-Gal antibodies, and considered to constitute
a major fraction of ‘non-Gal’ antibodies [19]. These xeno-
autoantibodies can interact with tumor-associated Neu5Gc,
thereby exerting dose-dependent effects: at a low dose they
facilitate tumor progression via chronic inflammation [20], while
at higher doses they inhibit tumor growth [21]. Furthermore, some
of these antibodies are biomarkers of carcinomas and potential
therapeutic agents [21]. Likewise, anti-Neu5Gc antibodies poten-
tially play a role in vascular inflammation disease states such as
atherosclerosis [22]. Thus, detection of overall anti-Neu5Gc
reactivity to multiple Neu5Gc-containing epitopes is desirable as
a screening method to detect risk, progression or therapeutic
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response in chronic inflammation-related diseases such as cancer
[21].
Kawasaki disease (KD) is the leading cause of acquired
pediatric heart disease in the developed world [23,24]. It is an
acute, self-llimited vasculitis associated with fever and mucocu-
taneous signs. At present there is no simple diagnostic test for
KD and diagnosis rather relies on clinical criteria that include:
prolonged high fever (.5 days), rash, conjunctival injection,
cervical lymphadenopathy, changes in the oral mucosa and
changes in the extremities [25,26]. In severe cases coronary
artery abnormalities (dilatation or aneurysm) are detected. KD
is treated with high dose intravenous immunoglobulin G (IVIG)
and aspirin, and anticoagulants for coronary artery aneurysms
[25–28]. In KD there is a marked activation of the immune
system with elevations of serum pro-inflammatory cytokines and
chemokines at the acute phase [29], including elevated antibody
responses to various antigens [30–32]. Among those, heterophile
antibodies with Hanganutziu-Deicher (H-D) specificity were
shown to be elevated in KD patients [33–35]. In those generic
assays the H-D antigen was not well defined, but was suggested
to contain Neu5Gc [34,35]. Thus, we hypothesized that anti-
Neu5Gc antibodies response can be detected in KD patients
and their levels could perhaps be associated with disease severity
and/or progression.
Currently, it is difficult to determine the overall level of anti-
Neu5Gc antibodies in individual human samples because these
antibodies recognize multiple Neu5Gc-epitopes that contain
terminal Neu5Gc at the tips of their glycan chains. Available
assays to detect human anti-Neu5Gc antibodies rely on the
difference between Neu5Ac and Neu5Gc, and require matched
sets of Neu5Ac-epitopes and Neu5Gc-epitopes. The final specific
Neu5Gc-reactivity is determined after subtraction of the matching
Neu5Ac-reactivity [9,15,16,21]. This method is likely to generate
some ‘false-negative’ signals because a fraction of anti-Neu5Gc
antibodies may cross-react with Neu5Ac and/or because anti-
Neu5Ac antibodies may be unrelated. In addition, such antibodies
with low affinity may overlap by cross-reacting with several
Neu5Gc-containing epitopes, as supported by ELISA inhibition
assays [16]. Mild periodate treatment, which truncates the side
chain of unmodified sialic-acid (9-O-acetylated Sia are resistant),
can also be used to ascribe Sia-specific binding but it is not
Neu5Gc-specific [21,36]. Alternatively, we previously described
sialoglycan microarrays with several individual Neu5Gc-epitopes
for detection of only a fraction of the overall anti-Neu5Gc
response for each unique Neu5Gc-epitope [21,37]. All these
methods require laborious and specific chemical synthesis of
matched Neu5Ac/Neu5Gc-pairs, and even then may be limited to
mono-specificities of certain Neu5Gc-epitopes. In contrast, we
here describe a novel robust assay that is simple, rapid and specific
to get an estimate of overall anti-Neu5Gc antibodies against
multiple Neu5Gc-epitopes. We apply this assay to evaluate anti-
Neu5Gc responses in Kawasaki disease patients and controls, and
show it to be comparable to the more sophisticated sialoglycan
microarray assay. Both assays revealed an elevated response in
acute KD patients with normal coronaries compared to patients
with aneurysm or dilated coronaries.
Materials and Methods
Ethics
Mice were maintained according to UCSD Institutional Animal
Care and Use Committee guidelines for laboratory animals
(IACUC permit S01227: ‘‘Evaluation of the Role of Glycans in
Normal Physiology, Malignancies and Immune Responses’’). Mice
were euthanized by CO2 inhalation with subsequent cardiac
bleeding. Human patients were enrolled at Rady Children’s
Hospital, San Diego after obtaining written parental informed
consent and subject assent, as appropriate. The study protocol
‘‘Human Research Protection Program’’ was reviewed and
approved by the UCSD Institutional Review Board. All data
were analyzed anonymously.
Antibodies and Lectins
We used purified human IgA, purified human IgG, horseradish
peroxidase (HRP)-goat-anti-mouse IgG (Fcc fragment specific),
HRP-streptavidin, Cy3-goat-anti-human IgG (H+L) (Jackson
ImmunoResearch Laboratories), HRP-conjugated goat-anti-hu-
man IgA (Calbiochem), HRP-goat-anti-human IgG (Bio-Rad) and
biotinylated lectins SNA, MAL-1 and MAL-2 (Vector Labs).
Mice
Wild-type (WT) and Cmah2/2 (Cmah-KO) mice [6] were bred in
a congenic C57BL/6 background and maintained according to
Institutional Animal Care and Use Committee guidelines for
laboratory animals (IACUC permit S01227: Evaluation of the
Role of Glycans in Normal Physiology, Malignancies and Immune
Responses). Mouse sera were obtained by terminal cardiac
bleeding.
Mice Sera Screening
Only mice sera free of mouse-anti-human IgG antibodies were
used. To screen for such sera, Costar 96-well plates were coated
with human IgG at 1 mg/well in coating buffer (50 mM sodium
carbonate-bicarbonate buffer, pH 9.5) then incubated overnight at
4uC. Wells were blocked for 2 hours at room temperature (RT)
with TBST (150 mM NaCl, 50 mM Tris pH 8, 0.1% Tween-20).
After removal of TBST, candidate mouse sera (diluted in TBST at
1:400) were added to triplicate wells at 100 ml/well then incubated
at RT for 2 hours. Wells were washed three times with TBST then
detection antibody (HRP-goat anti-mouse IgG Fcc fragment
specific, diluted 1:10,000 in TBST) was added at 100 ml/well and
incubated for 1 hour at RT. After washing three times with TBST,
wells were developed with O-phenylenediamine (0.5 mg/ml) in
citrate-PO4 buffer, pH 5.5, reaction was stopped with H2SO4 and
absorbance was measured at 490 nm wavelength on a Spectra-
Max M3 (Molecular Devices). Mouse sera that did not show
reactivity to human IgG were pooled and further analyzed.
Protein concentration of pooled sera was determined with
commercial BCA assay to be 90 mg/ml in the WT and 92 mg/
ml in the Cmah-KO.
DMB-HPLC Analysis
The Sia content of mouse serum glycoconjugates was analyzed.
Sias were released from glycoconjugates by acid hydrolysis using
0.1 M H2SO4 for 1 hours at 80uC. Free Sias were then derivatized
with 1,2-diamino-4,5-methylenedioxybenzene (DMB) and cleared
from proteins by Microcon-10 centrifugal filters then analyzed by
fluorescence detection on reverse-phase HPLC (DMB-HPLC).
Quantification of Sias was done by comparison with known
quantities of DMB-derivatized Neu5Ac [38]. Mouse sera Sia
content from WT and Cmah-KO was 2.560.2 mM and
2.160.5 mM, respectively. This is equivalent to 2762 pmole
Sia/mg protein in WT and 2365 pmole Sia/mg protein in Cmah-
KO (on average 9162 mg/ml, 2.360.4 mM and 2564 pmole Sia/
mg protein for both strains).
Detection of Anti-Neu5Gc Antibodies
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Mass Spectrometry Analysis
Analysis was done by the UCSD Glycotechnology Core
Resource. N-Glycans were released from pooled mouse sera by
PNGase-F [39] and O-glycans were released by alkaline reductive
beta-elimination [40]. These were then permethylated and
analyzed by MALDI-TOF and specific peaks confirmed by
tandem mass-spectrometry (ms/ms) [41].
ELISA
We tested binding of human serum and lectins to mouse serum
glycoconjugates by ELISA. Costar 96-well were coated overnight
at 4uC with saturating concentration (1 mg/well) of WT or Cmah-
KO pooled mouse sera (lacking mouse-anti-human IgG) or alpha-
Gal linked to polyacrylamide (250 ng/well; Gala1-3Galb1-
4GlcNAc-PAA) in coating buffer (50 mM sodium carbonate-
bicarbonate buffer, pH 9.5). Wells were blocked for 2 hours at RT
with PBS/OVA (PBS pH 7.3, 1% chicken ovalbumin (Sigma)).
After removal of buffer, human sera (1:100 diluted in PBS/OVA)
or lectins (0.1 mg/ml Bio-SNA, 4 mg/ml Bio-MAL-1, 4 mg/ml
Bio-MAL-2) were added to triplicate wells at 100 ml/well then
incubated at RT for 2 hours. Wells were washed three times with
PBST (PBS pH 7.3, 0.1% Tween-20), detection antibody was then
added (100 ml/well, 1:7,000 HRP-goat-anti-human IgG or
1:10,000 HRP-streptavidin (0.1 mg/ml) diluted in PBS) and
incubated for 1 hour at RT. After washing three times with
PBST, wells were developed with 0.5 mg/ml O-phenylenediamine
in citrate-PO4 buffer, pH 5.5, reaction was stopped with H2SO4
and absorbance was measured at a 490 nm wavelength on a
SpectraMax 250 (Molecular Devices).
Mild Periodate Treatment
To ascribe Sia specificity, mouse serum-coated ELISA plates
were treated with mild periodate to selectively cleave the Sia side-
chain [42]. Costar 96-well plates were coated overnight at 4uC
with mouse sera as above. Next, wells were decanted and freshly
prepared periodate solution (cold 2 mM sodium metaperiodate in
PBS pH6.5, 200 ml/well) was added followed by gentle shaking for
20 min at 4uC in the dark. The reaction was stopped by addition
of 50 ml of freshly prepared 100 mM sodium borohydride in PBS
pH 6.5 (final concentration of 20 mM) followed by 10 min
incubation at RT with gentle shaking (the borohydride inactivates
the periodate). Concurrently, as a mock control, periodate and
borohydride solutions were premixed at the same ratio (4:1) and
wells incubated (250 ml/well) side-by-side with the periodate-
treated wells. To remove resulting borates, wells were washed
three times (10 min each wash) with wash buffer (50 mM sodium
acetate pH 5.5, 100 mM NaCl) then three times with PBS pH 7.3.
Subsequently, wells were blocked and further processed as
described (ELISA/EIA assays).
Base Treatment
To remove 9-O-acetyl esters and render all Sias sensitive to mild
periodate treatment, mouse serum-coated ELISA plates were base
treated with 100 ml/well 0.1 M NaOH (final) at 37uC for 30 min,
followed by neutralization with 100 ml/well 0.1 M HCl (final).
Subsequently, plates were washed three times with PBS
pH 7.3 then with PBS pH 6.5, followed by mild periodate
treatment and development of ELISA with lectins as detailed.
ELISA Inhibition Assay (EIA)
We tested human serum binding specifically to WT mouse
serum Neu5Gc-glycoconjugates by EIA. Costar 96-well were
coated overnight at 4uC with saturating concentration (1 mg/well)
WT pooled mouse sera (lacking mouse-anti-human IgG) in
coating buffer (50 mM sodium carbonate-bicarbonate buffer,
pH 9.5). Wells were blocked for 2 hours at RT with PBS/OVA
(PBS pH 7.3, 1% chicken ovalbumin). During the blocking,
human serum was diluted 1:100 in EIA buffer (PBS pH 7.3, 1%
chicken ovalbumin and Cmah-KO pooled sera diluted at 1:4000,
thus containing ,2.3 mg protein/100 ml and ,57 pmole Sia/
100 ml) and incubated on ice for 2 hours. Next, PBS/OVA was
removed from wells and pre-treated human serum was added to
triplicate wells at 100 ml/well then incubated at RT for 2 hours.
Wells were washed three times with PBST (PBS pH 7.3, 0.1%
Tween-20) then detection antibody was added (100 ml/well HRP-
goat-anti-human IgG 1:7,000 diluted in PBS) and incubated for
1 hour at RT. After washing three times with PBST, wells were
developed with 0.5 mg/mlO-phenylenediamine in citrate-PO4
buffer, pH 5.5, reaction was stopped with H2SO4 and absorbance
was measured at a 490 nm wavelength on a SpectraMax M3
(Molecular Devices). For Quantification of overall anti-Neu5Gc
reactivity, each plate was also coated overnight with serial dilutions
of purified human Igs (IgA and IgG; 10–0.3 ng/well). The Igs
were coated side-by-side with WT mouse then all human serum
samples and Ig standard were developed on the same plate for
each Ig with HRP-goat-anti-human IgG or IgA.
Human Sera Samples
Patients were enrolled at Rady Children’s Hospital, San Diego
after obtaining parental informed consent and subject assent, as
appropriate. The study protocol was reviewed and approved by
the Institutional Review Board. All Kawasaki disease (KD)
patients (n = 10) met the standard case definition for KD: had
fever and at least 4 of the 5 standard clinical criteria (rash,
conjunctival injection, cervical lymphadenopathy, changes in the
oral mucosa, and changes in the extremities) or fever and 3 criteria
plus coronary artery abnormalities (dilatation or aneurysm; [26])
documented by echocardiography. Only patients diagnosed within
the first 10 days after fever onset were analyzed. Sequential
samples were obtained from KD patients with normal course of
disease (n = 5) or with coronary artery damage (n= 5) at three time
points: acute phase, 2 weeks later (sub-acute) and at convalescent
(1–3 months later). For controls we used age-similar healthy
controls (HC) or febrile controls (FCs). FC were children evaluated
in the emergency department who had fever for at least 3 days and
diagnosed with Epstein-Barr virus (EBV, n= 3) or herpes simplex
virus (HSP, n= 3). Whole blood was collected in red top tubes and
the serum was separated from the clot within one hour of
phlebotomy. Serum was stored at 4C for up to 72h and then
frozen at 280uC until use.
Sialoglycan Microarray Fabrication
Arrays were printed on Epoxide-derivatized Corning slides as
described [21] with some modifications to print layout as described
[37]. Epoxide-derivatized Corning slides were purchased from
Thermo Fisher Scientific (Pittsburgh, PA) and the arrays were
printed with SMT-S50, Classic silicon pins with 50650 mm tips
from Parallel Synthesis Technologies (Santa Clara, CA) using a
UCSF DeRisi Linear Servo Motor Microarrayer, generating
,70 mm diameter spots. Glycoconjugates were distributed into a
384-well source plates using 8 replicate wells per sample and 5 ml
per well (Version 11P2). Each glycoconjugate was prepared at
100 mM in an optimized print buffer (300 mM phosphate buffer,
pH 8.4). To monitor printing quality we used replicate-wells of
human IgG (Jackson ImmunoResearch) at 150 mg/ml (in PBS) for
each printing-pin. 8 pins were used, with each pin printing 6
replicate spots/well (by using the 384-well source plate 6 times), 24
Detection of Anti-Neu5Gc Antibodies
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spots/row with spacing of 180 mm. One complete array was
printed with each pin generating 8 sub-array blocks on each slide
(within approx 16 hours/,100 slides). The humidity level in the
arraying room was maintained at about 70% during printing.
Printed slides were left on arrayer deck over-night, allowing
humidity to drop to ambient levels. Next, the print order of the
slides was recorded (using Fine Tip Black lab marker from VWR)
and slides were packed, vacuum-sealed and stored in a desiccant
chamber at RT until used. Slides were printed in one batch of
,100 slides.
Array Binding Assays
Each serum was tested in two duplicate sub-arrays on two
different slides and data was averaged. Slides were incubated for 1
hour in a staining dish with 50uC pre-warmed blocking solution
(0.05 M ethanolamine in 0.1 M Tris, pH 9.0) to block the
remaining reactive groups on the slide surface, then washed twice
with 50uC pre-warmed dH2O. Slides were centrifuged at 2006g
for 3 min. Slides were then fitted with ProPlateTM Multi-Array
slide module (Invitrogen) to divide into the sub-arrays then
blocked with 200 ml/sub-array of blocking buffer (PBS/OVA, 1%
w/v ovalbumin in PBS pH 7.3) for 1 hour at room temperature
(RT) with gentle shaking. Next, the blocking solution was aspirated
and 1:100 diluted human serum samples were added to each slide
(in PBS/OVA, 200 ml/sub-array) and allowed to incubate with
gentle shaking for 2 hours at RT. Slides were washed three times
with PBST (PBS containing 0.1% Tween) then with PBS for
10 min/wash with shaking. Bound antibodies were detected by
incubating with 200 ml/sub-array of the Cy3-goat-anti-human
IgG (H+L) at 1:500 diluted in PBS (1.5 mg/ml) at RT for 1 hour.
Slides were washed three times with PBST (PBS, 0.1% Tween)
then with PBS 10 min/wash followed by removal from ProPla-
teTM Multi-Array slide module and immediately dipping slide in a
staining dish with dH2O for 10 min with shaking, then centrifuged
at 2006g for 3 min. Dry slides were vacuum-sealed and stored in
dark until scanning the following day.
Array Slide Processing
Processed slides were scanned and analyzed as described
[21,37] at 10 mm resolution with a Genepix 4000B microarray
scanner (Molecular Devices Corporation, Union City, CA) using
350 gain. Image analysis was carried out with Genepix Pro 6.0
analysis software (Molecular Devices Corporation). Spots were
defined as circular features with a variable radius as determined by
the Genepix scanning software. Local background subtraction was
performed.
Statistical analysis. Statistical analysis conducted with
Prism 5 with the specific methods as indicated in the figure
legends.
Results and Discussion
Principles for Simple Detection of Human Anti-Neu5Gc-
Antibody Reactivity
To detect overall anti-Neu5Gc antibody reactivity in human
samples we developed a simple method in which we exploit two
mouse models that differ only by Neu5Gc-presence (wild-type;
WT) or Neu5Gc-absence (Cmah2/2 knockout; Cmah-KO). Hu-
mans have circulating antibodies recognizing various antigens,
including anti-Neu5Gc antibodies and possibly human-anti-mouse
antibodies. We hypothesized that when human antibodies
reactivity is tested with WT mouse sample as target, both types
of antibodies might be detected (Fig. 1A). However, when tested
on Cmah-KO mouse sample as target, only human-anti-mouse
reactivity would be detected with no anti-Neu5Gc reactivity, due
to the lack of Neu5Gc-epitopes (Fig. 1A). This difference could
allow use of Cmah-KO samples as an inhibitor for human-anti-
mouse reactivity, thereby leaving only signal that is highly specific
for Neu5Gc-epitopes and that could be revealed by appropriate
tagged-detection system (Fig. 1B). To further confirm the signal is
Sia-specific, mild periodate oxidation can be used to truncate the
Sia side chain (Fig. 1C). This would specifically abolish Sia-
dependent binding but not human-anti-mouse reactivity (Fig. 1D).
To demonstrate this method, we chose to use mouse serum from
both strains in an ELISA inhibition assay based format (EIA) to
detect human serum anti-Neu5Gc antibodies on coated WT
mouse serum, using Cmah-KO mouse serum to inhibit non-
Neu5Gc reactivity (Fig. 1B–D).
Characterizing Serum from Wild-Type and Cmah-KO Mice
To allow use of mouse serum as targets for human antibodies
binding, we initially screened individual mouse sera for reactivity
against human antibodies (data not shown), and then used only
those that do not show mouse-anti-human reactivity (to avoid false
positives). Such mouse sera were collected and pooled from either
WT or Cmah-KO mice. The sera from both strains are expected to
have similar protein profiles yet different glycosylation patterns,
mainly the presence or absence of Neu5Gc, due to deactivation of
the CMAH enzyme in the Cmah-KO. Analysis of the sialic acid
(Sia) content by DMB-HPLC confirmed that Cmah-KO sera
contain only Neu5Ac, while the WT sera contain mostly Neu5Gc
(,9069%; Fig. 2A).
Sia carry a characteristic acidic carboxylate group and have a 9-
carbon backbone. They normally cap glycoconjugates and are
linked to underlying sugars by various linkages (Siaa223 to
galactose, Siaa226 to galactose or N-acetylgalactosamine or
Siaa228 to another Sia) [2]. To evaluate the Neu5Gc-epitopes
targets in WT mouse sera, we first analyzed the Sia-linkage on
serum sialoglycoproteins by ELISA using the Sia-specific lectins
SNA (specific for Siaa2-6), MAL-1 and MAL-2 (both specific for
Siaa2-3) [37,43,44]. This analysis revealed that both WT and
Cmah-KO sera contain both Siaa2-3/6-linked glycoconjugates
with the Siaa2-6-linked being more abundant (Fig. 2B). To
demonstrate Sia-specificity, we used mild periodate oxidation
followed by reduction with borohydride that specifically generates
a truncated-Sia with a terminal hydroxyl at carbon 7. The
resulting modified Sia has two less carbons (carbons 8 and 9), but
maintains the negative charge (Fig. 1C) [37,45]. Lectin binding
was reduced after periodate treatment of the coated sialoglyco-
conjugates, demonstrating Sia-specificity (Fig. 2B). The residual
low lectins binding observed after periodate treatment suggests the
presence of O-acetylated Sia (Fig. 2B). Sia can be modified by O-
acetyl esters at positions C4, C7, C8, and/or C9 (Fig. 1C). C9
esters can serve as protecting groups rendering O-acetylated-Sia
insensitive to periodate oxidation [46,47]. However, periodate
sensitivity can be restored if the O-acetyl esters are removed by
mild base treatment [46,47]. Indeed, when the coated sialoglyco-
conjugates were first treated with base then followed by periodate
treatment, residual lectin binding was completely abolished
(Fig. 2C), thereby verifying the presence of O-acetylated-Sia in
mouse sera. Finally, mass-spectrometry analysis of N-linked and O-
linked glycans of WT and Cmah-KO sera revealed the most
common sialoglycan structures. This included mono/di-sialylated
bi-antennary N-glycans (fucosylated or non-fucosylated) and linear
or branched sialylated O-glycans (Fig. 2D). In WT sera,
Neu5Gc:Neu5Ac ratio is 9:1 for N-glycans and 5:1 for O-glycans.
In general, the N-glycans are more abundant than the O-glycans
(,630 higher in the WT sera).
Detection of Anti-Neu5Gc Antibodies
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Detection Of Specific Anti-Neu5Gc Antibody Reactivity in
Human Serum: Proof of Principle
To demonstrate this method we tested a previously character-
ized normal human serum (S34) that has high IgG reactivity with
multiple Neu5Gc-epitopes [16,21]. In ELISA, S34 showed strong
IgG binding to the Neu5Gc-positive WT mouse sera and lower
binding to the Neu5Gc-deficient Cmah-KO mouse sera (,20% of
WT; Fig. 3A). This suggested strong reactivity to Neu5Gc-epitopes
with low binding to other mouse epitopes. We then used ELISA
inhibition assay (EIA), in which S34 was pre-incubated with
serially diluted Cmah-KO mouse sera to remove human-anti-
mouse reactivity, and it was then allowed to bind mouse sera
coated targets. As the concentration of inhibitor increased, S34
showed dramatically reduced binding to Cmah-KO sera coated
targets (Fig. 3B). In contrast, on WT sera coated targets, there was
,20% maximal decrease in S34 binding with an optimal range of
diluted Cmah-KO inhibitor 1:4000 for S34; Fig. 3B). To further
prove Sia-specificity, mild periodate treatment was used in the
presence or absence of Cmah-KO inhibitor (Fig. 3C). This clearly
demonstrated the loss of anti-mouse reactivity only when inhibitor
was present and the abolishment of binding signal after mild
periodate treatment, thus indicating specific anti-Neu5Gc reactiv-
ity (Fig. 3C). These findings matched our hypothesis as outlined in
Fig. 1 and further confirmed for IgG and IgA using other normal
human sera (data not shown). Of note, S34 has strong anti-
Neu5Gc IgG reactivity [16] and low reactivity to mouse sera
antigens. Other sera may have different levels of reactivities to
these antigens (higher/lower for both antigens) thus the concen-
tration of the inhibitor may need to be optimized to match such
different profiles.
Anti-Neu5Gc Antibodies Reactivity in Kawasaki Disease
To validate the simple detection of such antibodies in a disease
context, we tested serum from patients with KD that is the leading
cause of acquired heart disease in children [23,24]. We
hypothesized that anti-Neu5Gc antibodies may be detected in
KD patients for several reasons. First, these antibodies appear in
infants coinciding with exposure to Neu5Gc-containing foods
(baby formula and red meat products) [18]. Second, anti-Neu5Gc
antibodies have been shown to contribute to human cardiovascu-
lar diseases [22]. Lastly, it has been suggested that heterophile
antibodies to H-D antigen, that presumably contained Neu5Gc,
are elevated in KD patients [33–35].
A total of 42 sera samples were obtained from 10 KD patients
and 12 controls (as detailed in Fig. 4A). Sera were serially collected
from KD patients (age range 5m –4y3m) at three stages of the
disease: before treatment with IVIG during the acute phase and
after treatment with IVIG at 2 weeks (sub-acute phase) and 1–3
months (convalescence phase). In addition, KD patients were
selected to represent various degrees of coronary artery (CA) status
Figure 1. A simple method to detect overall human anti-Neu5Gc reactivity. A. Human antibodies can bind to mouse glycoproteins from WT
(Neu5Gc-positive) or Cmah-KO (Neu5Gc-deficient) mice revealing anti-Neu5Gc and/or general anti-mouse reactivity. B. Illustration of the principles of
EIA method that can separate specific anti-Neu5Gc reactivity from anti-mouse reactivity. Human antibodies are pre-incubated with Cmah-KO sera to
absorb out anti-mouse reactivity, and binding to WT sera then reveals Neu5Gc-reactivity (grey circles =mouse glycoproteins; purple
diamonds=Neu5Ac-containing glycoconjugates; red diamonds =Neu5Gc-containing glycoconjugates). C. Treatment of WT sialo-glycoconjugates
with mild periodate cleaves the sialic acid side chain. D. Periodate pre-treatment of glycocojugates can demonstrate sialic acid specific binding but
has no effect on anti-mouse reactivity.
doi:10.1371/journal.pone.0058443.g001
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during disease progression. Five of the KD patients had normal
CA (CA1), two had aneurysms (CA2) and three had dilated
arteries (CA3). The controls were comprised of age-matched sera
from 6 healthy children (age range 10m –4y10m), and 6 febrile
patients (age range 11m –4y9m) diagnosed with either Epstein-
Barr virus (EBV) or herpes simplex virus (HSP) (Fig. 4A).
Serum samples were qualitatively analyzed by EIA to detect
overall anti-Neu5Gc IgA and IgG antibodies at three stages of the
disease (acute, sub-acute, convalescence) compared to the controls
(Fig. 4B). This revealed an elevated response in KD patients
compared to all control sera in the acute phase. Anti-Neu5Gc IgA
showed further increase in the sub-acute phase that began to
resolve at convalescence. A similar trend was also seen for anti-
Neu5Gc IgG, although in this case the elevated response may have
been partly attributed to the administered therapeutic human IgG
(IVIG) that contains anti-Neu5Gc IgGs [17] (Fig. 4B). We also
tested by ELISA the common antibodies to the related carbohy-
drate xeno-antigen, alpha-Gal [19,48]. Anti-Neu5Gc and anti-
alpha-Gal antibodies are both generated in humans during infancy
[18]. However, in contrast to the variable nature of Neu5Gc-
epitopes, the alpha-Gal epitope is a single structure (Gala1-
3Galb1-4GlcNAc-R) [48] [19]. In general, anti-alpha-Gal IgA and
IgG showed similar antibody response profiles to anti-Neu5Gc
antibodies (Fig. 4B). Taken together, these data suggest that the
elevated anti-Neu5Gc antibody responses are not unique, but
rather fit with previous observations of an overall polyclonal B-cell
response [30–32]. However, we noticed that those elevated
responses were largely observed in KD patients with normal
coronary arteries (CA1) rather than with damaged ones (CA2/3)
(EIA assay conducted while blinded to CA status, that was
revealed only after data analysis). Subsequent quantitative analysis
of these antibodies in the acute phase demonstrated that compared
to control sera there is significant elevated anti-Neu5Gc IgA and
IgG only in patients with CA1 but not with CA2/3 (Fig. 4C). In
line with IgG and IgA isotype relative abundance in sera [49,50],
anti-Neu5Gc IgG levels were greater than those of anti-Neu5Gc
IgA. Although anti-alpha-Gal antibodies showed a similar profile,
their levels were ,5 fold lower compared to anti-Neu5Gc
Figure 2. Sialic acid characteristics of sera from WT and Cmah-KO Mice. A. DMB-HPLC analysis of mouse sera confirms that WT is Neu5Gc-
positive while Cmah-KO is Neu5Gc-deficient. B. Lectin binding on mouse sera demonstrates both Siaa2-6 (SNA) and Siaa2-3 (MAL1/2)
glycoconjugates in both WT and Cmah-KO. After periodate treatment the signal is reduced demonstrating Sia specificity. The periodate-resistant
signal suggest 9-O-acetylated Sias. C. Pre-treatment of coated-wells with base removes periodate resistant signals (white bars in B compared to C),
confirming that some of the Sia are modified with 9-O-acetylation. D. Mass-spectrometry analysis of N-linked and O-linked glycans of WT and Cmah-
KO sera reveals the most common sialoglycan structures. Each figure is representative of at least two independent experiments. Bars are mean6 s.d.
of triplicates (A–C).
doi:10.1371/journal.pone.0058443.g002
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antibodies (Fig. 4C). The alpha-Gal epitope is not expressed in
humans (or other old-world primates) and cannot be taken up
through the diet, but is rather immunogenic on gut bacteria [19].
In contrast, Neu5Gc is an immunogenic dietary carbohydrate that
metabolically incorporates into human cells with its subsequent
presentation on multiple glycoconjugates on the cell surface and
secreted glycoconjugates [9–11]. In mouse models, the role of anti-
Neu5Gc antibodies in cancer may be determined by their levels,
with low levels stimulating disease [20] but high levels inhibiting
tumor growth [21]. In addition, patients with metastatic carcino-
mas may have lower levels of anti-Neu5Gc antibodies, possibly
due to their absorption by tumor cells on elevated tumor burden
[21]. Therefore, variable levels of anti-Neu5Gc antibodies in KD
patients may have a biological significance.
To independently validate these findings, we conducted a more
detailed analysis of anti-Neu5Gc IgG in controls and acute-KD
sera samples on a sialoglycan microarray. This array is printed
with various natural Neu5Gc-glycans side-by-side with their
matched Neu5Ac-glycans that differ by only a single oxygen atom
[21,37]. Consistent with the antibody reactivity by EIA (Fig. 4C),
binding profiles on the array revealed distinctively stronger broad
reactivity to multiple Neu5Gc-glycan epitopes in KD sera with
CA1 compared to CA2/3 or the controls, while no significant
differences observed for the corresponding control Neu5Ac-
glycans (Fig. 5A–B). This broad binding profile suggests that
while these antibodies are highly specific for Neu5Gc-containing
epitopes, many of them are likely cross-reacting with several
distinctive Neu5Gc-epitopes. To qualitatively compare between
the detection of antibodies by sialoglycan microarray versus the
newly developed EIA, the antibody reactivity on Neu5Ac/
Neu5Gc-glycans by microarray was averaged per donor sera
and compared between the sera groups. Statistical analysis
revealed a significant difference only for Neu5Gc-glycans between
controls and KD patients with CA1 (Fig. 5C). This profile exactly
matched the profile of anti-Neu5Gc IgG obtained by the EIA
method (Fig. 5C). Moreover, direct comparison of these anti-
Neu5Gc IgG values obtained by the two methods showed strong
correlation (Fig. 5D). The differences in antibody response among
the 3 KD groups based on coronary artery status may suggest that
immunologic differences are linked to disease outcome. Altogeth-
er, these findings strongly support the EIA as a valid and rapid
method for detection of overall anti-Neu5Gc reactivity in human
sera samples.
Figure 3. Specific detection of anti-Neu5Gc IgG in normal human serum. A. Plates were coated with WT or Cmah-KO mouse sera and Anti-
Neu5Gc IgG of human serum S34 [16] tested by ELISA. B. Plates were coated with WT or Cmah-KO mouse sera, then human serum S34 IgG binding
tested by ELISA (0) or by EIA after pre-incubation of S34 with Cmah-KO mouse sera (as depicted in Fig. 1B). EIA specifically inhibited anti-Cmah-KO
(anti-mouse) reactivity, resulting in Neu5Gc-specific reactivity on WT coated plates. For S34, the optimal Cmah-KO inhibitor is at 1:4000 dilution. C.
Sialic acid specific binding demonstrated by mock versus mild periodate pre-treatment of coated wells. Human serum S34 (1:100) tested over WT
mouse serum without inhibitor (0) or by EIA method with diluted Cmah-KO mouse sera. In the presence of Cmah-KO inhibitor, S34 binding to WT was
abolished compared to mock treated wells hence specificity is towards sialylated-(Neu5Gc)-glycans. Numbers 1–4 refer to the specific steps predicted
by the model, as described in Fig. 1D. Each figure is representative of at least two independent experiments. Bars are mean6 s.d. of triplicates (A–C).
doi:10.1371/journal.pone.0058443.g003
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Conclusions
Detection of overall anti-Neu5Gc reactivity needs to be studied
as a potential method to detect risk, progression or therapeutic
responses in chronic inflammation-related diseases such as cancer
and cardiovascular diseases. Here we describe a rapid and efficient
method to detect overall anti-Neu5Gc responses in human sera.
We have developed this method by using WT and Cmah-KO
mouse sera (respectively Neu5Gc-positive or -negative), which
contain multiple Sia-epitopes with either native- or modified-Sia
(O-acetylated) that are variously linked to underlying glycans.
Similarly, WT and Cmah-KO matched sera from other organisms
(e.g., porcine) can be used. In fact, any matched tissue from WT
and Cmah-KO can theoretically be used, because the presence and
absence of Neu5Gc is likely respectively maintained. Different
matched-tissues/organisms may represent additional/other
Neu5Gc-epitopes not necessarily present in sera, and should be
studied in the future. Here, we also used the Cmah-KO sera as ‘in-
solution’ inhibitor to block non-Sia binding and facilitate rapid
detection. However, human-anti-mouse reactivity might also be
removed from candidate human sera prior to the detection assay,
for example by attaching the Cmah-KO sera inhibitor to magnetic
beads (or other solid surface) for pre-absorption. In addition, other
detection methods can be used instead of ELISA; for example dot
blot that would result in a deposition of insoluble color on a
membrane leaving a colored dot where anti-Neu5Gc reactivity is
detected (much like a ‘pregnancy-test’). This method might also be
applicable to specifically detect human anti-Neu5Gc reactivity in
various human samples other than serum, such as plasma, synovial
fluid, tissue extracts etc. This rapid and robust assay can now be
used for detection of overall anti-Neu5Gc reactivity as a potential
screening method to monitor risk, progression or therapeutic
responses in various inflammation-mediated conditions.
Figure 4. Characterization of anti-Neu5Gc IgA and IgG in Kawasaki disease patients’ sera. A. Details of the cohort of sera used for analysis
of antibodies. Coronary arteries (CA) status represents normal (CA1) or damaged with aneurysm (CA2) or dilatation (CA3). B. Analysis of IgA and IgG
antibodies against Neu5Gc-epitopes (by EIA over WT sera) and alpha-Gal-epitope (by ELISA) in controls versus KD patients’ sera at acute (at diagnosis
prior to treatment), sub-acute (at 2 weeks post-IVIG) and convalescent phases (1–3 months post IVIG) of disease. KD sera revealed increased
antibodies responses in the sub-acute compared to the acute phase (repeated measures One-Way ANOVE with Tukey’s multiple comparison test:
anti-Neu5Gc IgA P= 0.0213, IgG P= 0.0003; anti-alpha-Gal IgA ns, IgG P,0.0001). Representative of two independent experiments (data for each
individual is provided in Fig. S1). C. Quantitative analysis of anti-Neu5Gc (EIA) and anti-alpha-Gal (ELISA) IgA and IgG responses in sera samples
conducted against the respective immunoglobulin (Ig) standard curves. All sera samples were tested in duplicates on a single plate for each Ig. KD
sera with CA1, but not with CA2/3, show significant increased antibodies levels compared to controls as summarized (One-Way ANOVA with Tukey’s
multiple comparison test; anti-Neu5Gc IgA P= 0.0194, IgG P= 0.0045; anti-alpha-Gal IgA P= 0.0124, IgG P= 0.1479). Data from two independent
experiments.
doi:10.1371/journal.pone.0058443.g004
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